Pharma Tech

ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer

Oct 25, 2026, 10:35 PM

Read Full Article → ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer

Translate article text

Choose a language and wait for the translated text.

GSK’s Mo-Rez is projected to reach global annual sales of $540m by 2032 based on GlobalData’s analyst consensus forecast.